x

Please fill out this short user survey of only 3 questions in order to help us improve the site. We appreciate your feedback!
Public views on vaccine pricing
Last registered on April 15, 2021

Pre-Trial

Trial Information
General Information
Title
Public views on vaccine pricing
RCT ID
AEARCTR-0007522
Initial registration date
April 14, 2021
Last updated
April 15, 2021 6:19 AM EDT
Location(s)

This section is unavailable to the public. Use the button below to request access to this information.

Request Information
Primary Investigator
Affiliation
Monash University
Other Primary Investigator(s)
PI Affiliation
Monash University
PI Affiliation
Monash University
Additional Trial Information
Status
In development
Start date
2021-04-17
End date
2021-05-31
Secondary IDs
Abstract
Global pricing of vaccines against infectious diseases is an important determinant of global public health outcomes as it affects the production and distribution of vaccines across countries. Pricing of vaccines remains a contentious issue because there is a dilemma: ensuring vaccines are affordable to poorer countries which have a relatively high burden of disease compared to richer countries, while also providing pharmaceutical firms with sufficient incentives for the research, development and innovation of vaccines. As a result, there have been calls for equity-based pricing, where prices are based on a country’s ability to pay. Using an online randomised controlled survey experiment, we will analyse the relative effects of providing different types of information on public support for equity-based pricing of vaccines.
External Link(s)
Registration Citation
Citation
Chan, Yee Wah Lisa, Birendra Rai and Liang Choon Wang. 2021. "Public views on vaccine pricing." AEA RCT Registry. April 15. https://doi.org/10.1257/rct.7522-1.0.
Experimental Details
Interventions
Intervention(s)
Intervention Start Date
2021-04-17
Intervention End Date
2021-05-31
Primary Outcomes
Primary Outcomes (end points)
1) A binary variable that is equal to 1 if the participant chooses prices consistent with equity-based pricing, and 0 otherwise.

2) A binary variable that is equal to 1 if the participant responds "Yes" to the question "Should the firm make some overall profit from its pricing across different countries?", and 0 otherwise.

There are a number of different scenarios and stages. Therefore, outcome variables are defined at the scenario level and stage level.
Primary Outcomes (explanation)
Secondary Outcomes
Secondary Outcomes (end points)
Secondary Outcomes (explanation)
Experimental Design
Experimental Design
The study will involve a randomised controlled choice experiment where we will try to infer the extent of public support for equity-based pricing of vaccines across different countries. The experiment will involve multiple treatment arms. Each arm will contain several stages, but the main difference will be whether and what type of information is provided to participants before they make their pricing decisions.

Experimental Design Details
Not available
Randomization Method
Randomizer in Qualtrics with the option "evenly present elements".
Randomization Unit
Individual
Was the treatment clustered?
Yes
Experiment Characteristics
Sample size: planned number of clusters
720 individuals
Sample size: planned number of observations
1440 observations (720 individuals x 2 stages)
Sample size (or number of clusters) by treatment arms
90 individuals per treatment arm
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB
INSTITUTIONAL REVIEW BOARDS (IRBs)
IRB Name
Monash University Human Research Ethics Committee
IRB Approval Date
2020-12-21
IRB Approval Number
27264
Analysis Plan

There are documents in this trial unavailable to the public. Use the button below to request access to this information.

Request Information